Kahira Pharmaceuticals’ profits fall 39% in 6 months: Egypt

Reuters Images

Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use

Staff Writer, Arab Finance

EGYPT PHARMACEUTICAL

PHOTO

Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 39% year-on-year decline in net profit after tax for the first half (H1) of fiscal year (FY) 2022/2023, according to the company’s unaudited financial indicators filed to the Egyptian Exchange (EGX).

CPCI’s net profit after tax stood at EGP 50.078 million for the six-month period ended December 31st 2022, compared to profits of EGP 82.057 million in FY H1 2021/2022.

Revenue amounted to EGP 449.077 million in H1 FY 2022/2023, down from EGP 527.104 million in the comparative period a FY earlier.

Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.